Company profile VRCA

Verrica Pharmaceuticals Inc
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical tri...al for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania. Show More
Quarter analysis & expected interestLast update: February 07 2024 22:54:42.

After 38 days of this quarter the interest is at 43.0. Based on that we can calculate that during remaining 53 days it will total up to 103.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019109
118
8.3% QoQ
96
-18.6% QoQ
155
61.5% QoQ
2020 30
-72.5% YoY -80.6% QoQ
88
-25.4% YoY 193.3% QoQ
197
105.2% YoY 123.9% QoQ
139
-10.3% YoY -29.4% QoQ
2021 120
300.0% YoY -13.7% QoQ
243
176.1% YoY 102.5% QoQ
136
-31.0% YoY -44.0% QoQ
91
-34.5% YoY -33.1% QoQ
2022 98
-18.3% YoY 7.7% QoQ
176
-27.6% YoY 79.6% QoQ
197
44.9% YoY 11.9% QoQ
54
-40.7% YoY -72.6% QoQ
2023 101
3.1% YoY 87.0% QoQ
167
-5.1% YoY 65.3% QoQ
242
22.8% YoY 44.9% QoQ
109
101.9% YoY -55.0% QoQ
2024 43
-57.4% YoY -60.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Verrica Pharmaceuticals search interestLast update: February 07 2024 22:54:42.
Correlation coefficient between keyword and revenue is 0.32
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 22:54:43.

The average 5 years interest of Verrica Pharmaceuticals was 10.42 per week.
The last year interest of Verrica Pharmaceuticals compared to the last 5 years has changed by 14.2%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 29.49%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Verrica Pharmaceuticals Verrica Pharmaceuticals stock to provide analysis

Correlation between past revenue and Verrica Pharmaceuticals Verrica Pharmaceuticals stock search interest

There is not enough data for Verrica Pharmaceuticals Verrica Pharmaceuticals stock to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Verrica Pharmaceuticals Verrica Pharmaceuticals stock to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 22:54:46.

After 38 days of this quarter the interest is at 37.0. Based on that we can calculate that during remaining 53 days it will total up to 89.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
20190
204
inf% QoQ
230
12.7% QoQ
162
-29.6% QoQ
2020 137
inf% YoY -15.4% QoQ
81
-60.3% YoY -40.9% QoQ
26
-88.7% YoY -67.9% QoQ
167
3.1% YoY 542.3% QoQ
2021 197
43.8% YoY 18.0% QoQ
77
-4.9% YoY -60.9% QoQ
55
111.5% YoY -28.6% QoQ
145
-13.2% YoY 163.6% QoQ
2022 224
13.7% YoY 54.5% QoQ
334
333.8% YoY 49.1% QoQ
127
130.9% YoY -62.0% QoQ
121
-16.6% YoY -4.7% QoQ
2023 96
-57.1% YoY -20.7% QoQ
138
-58.7% YoY 43.8% QoQ
120
-5.5% YoY -13.0% QoQ
124
2.5% YoY 3.3% QoQ
2024 37
-61.5% YoY -70.2% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and VP-102 search interestLast update: February 07 2024 22:54:45.
Correlation coefficient between keyword and revenue is -0.02
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 22:54:46.

The average 5 years interest of VP-102 was 10.78 per week.
The last year interest of VP-102 compared to the last 5 years has changed by -8.16%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -29.79%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 22:54:49.

After 38 days of this quarter the interest is at 244.0. Based on that we can calculate that during remaining 53 days it will total up to 584.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019357
784
119.6% QoQ
808
3.1% QoQ
595
-26.4% QoQ
2020 516
44.5% YoY -13.3% QoQ
658
-16.1% YoY 27.5% QoQ
620
-23.3% YoY -5.8% QoQ
583
-2.0% YoY -6.0% QoQ
2021 697
35.1% YoY 19.6% QoQ
672
2.1% YoY -3.6% QoQ
685
10.5% YoY 1.9% QoQ
539
-7.5% YoY -21.3% QoQ
2022 618
-11.3% YoY 14.7% QoQ
824
22.6% YoY 33.3% QoQ
851
24.2% YoY 3.3% QoQ
613
13.7% YoY -28.0% QoQ
2023 871
40.9% YoY 42.1% QoQ
954
15.8% YoY 9.5% QoQ
990
16.3% YoY 3.8% QoQ
733
19.6% YoY -26.0% QoQ
2024 244
-72.0% YoY -66.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and molluscum contagiosum treatment search interestLast update: February 07 2024 22:54:49.
Correlation coefficient between keyword and revenue is 0.06
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 22:54:49.

The average 5 years interest of molluscum contagiosum treatment was 54.66 per week.
The last year interest of molluscum contagiosum treatment compared to the last 5 years has changed by 21.81%.
The interest for molluscum contagiosum treatment is trending.
The last year interest is quite higher compared to 5 years ago. It has increased by 27.28%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VP-315 to provide analysis

Correlation between past revenue and VP-315 search interest

There is not enough data for VP-315 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VP-315 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for oncolytic peptide therapy to provide analysis

Correlation between past revenue and oncolytic peptide therapy search interest

There is not enough data for oncolytic peptide therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for oncolytic peptide therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 22:54:54.

After 38 days of this quarter the interest is at 233.0. Based on that we can calculate that during remaining 53 days it will total up to 558.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019324
575
77.5% QoQ
642
11.7% QoQ
469
-26.9% QoQ
2020 555
71.3% YoY 18.3% QoQ
455
-20.9% YoY -18.0% QoQ
463
-27.9% YoY 1.8% QoQ
443
-5.5% YoY -4.3% QoQ
2021 483
-13.0% YoY 9.0% QoQ
603
32.5% YoY 24.8% QoQ
554
19.7% YoY -8.1% QoQ
602
35.9% YoY 8.7% QoQ
2022 614
27.1% YoY 2.0% QoQ
667
10.6% YoY 8.6% QoQ
642
15.9% YoY -3.7% QoQ
702
16.6% YoY 9.3% QoQ
2023 715
16.4% YoY 1.9% QoQ
731
9.6% YoY 2.2% QoQ
679
5.8% YoY -7.1% QoQ
716
2.0% YoY 5.4% QoQ
2024 233
-67.4% YoY -67.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and basal cell carcinoma treatment search interestLast update: February 07 2024 22:54:53.
Correlation coefficient between keyword and revenue is -0.73
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 22:54:55.

The average 5 years interest of basal cell carcinoma treatment was 45.64 per week.
The last year interest of basal cell carcinoma treatment compared to the last 5 years has changed by 18.03%.
The interest for basal cell carcinoma treatment is trending.
The last year interest is quite higher compared to 5 years ago. It has increased by 23.73%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VP-103 to provide analysis

Correlation between past revenue and VP-103 search interest

There is not enough data for VP-103 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VP-103 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 22:54:58.

After 38 days of this quarter the interest is at 199.0. Based on that we can calculate that during remaining 53 days it will total up to 477.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019292
509
74.3% QoQ
647
27.1% QoQ
527
-18.5% QoQ
2020 390
33.6% YoY -26.0% QoQ
641
25.9% YoY 64.4% QoQ
487
-24.7% YoY -24.0% QoQ
646
22.6% YoY 32.6% QoQ
2021 448
14.9% YoY -30.7% QoQ
643
0.3% YoY 43.5% QoQ
459
-5.7% YoY -28.6% QoQ
347
-46.3% YoY -24.4% QoQ
2022 481
7.4% YoY 38.6% QoQ
569
-11.5% YoY 18.3% QoQ
488
6.3% YoY -14.2% QoQ
485
39.8% YoY -0.6% QoQ
2023 646
34.3% YoY 33.2% QoQ
830
45.9% YoY 28.5% QoQ
723
48.2% YoY -12.9% QoQ
606
24.9% YoY -16.2% QoQ
2024 199
-69.2% YoY -67.2% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and plantar warts treatment search interestLast update: February 07 2024 22:54:58.
Correlation coefficient between keyword and revenue is -0.29
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 22:54:59.

The average 5 years interest of plantar warts treatment was 42.55 per week.
The last year interest of plantar warts treatment compared to the last 5 years has changed by 25.5%.
The interest for plantar warts treatment is trending.
The last year interest is quite higher compared to 5 years ago. It has increased by 27.66%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for VRCA
Earnings date: 2024-03-06 After close
Company name: Verrica Pharmaceuticals Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-22T05:00:00-07:00

GlobeNewswire
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility

2026-09-10T05:05:00-07:00

GlobeNewswire
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

2026-09-08T05:00:00-07:00

GlobeNewswire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

2026-08-27T05:00:00-07:00

GlobeNewswire
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

2026-08-06T13:05:00-07:00

GlobeNewswire
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

2026-08-06T13:01:00-07:00

GlobeNewswire
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

2026-07-30T05:00:00-07:00

GlobeNewswire
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

2026-07-21T05:00:00-07:00

GlobeNewswire
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

2026-06-22T05:05:00-07:00

GlobeNewswire
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

2026-05-28T12:05:00Z

GlobeNewswire
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

2026-05-26T10:51:11Z

Analyst Upgrades
HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12

2026-05-13T12:00:00Z

GlobeNewswire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

2026-05-12T20:01:00Z

GlobeNewswire
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

2026-05-05T20:05:00Z

GlobeNewswire
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

2026-05-05T12:00:00Z

GlobeNewswire
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026